Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes

Abstract

Background Giant pituitary adenoma (≥4 cm) is a rare tumor whose clinical features and prognosis are not well known.

Aim To evaluate the clinical characteristics and therapeutic outcomes of giant non-functioning PA (gNFPA).

Patients and Methods A retrospective multicenter study of gNFPA patients diagnosed in a 12-year period was performed. In each patient, clinical data and therapeutic outcomes were registered.

Results Forty patients (24 men, age 54.2 ± 16.2 years) were studied. The maximum tumor diameter [median (interquartile range)] was 4.6 cm (4.1–5.1). Women had larger tumors [4.8 cm (4.2–5.4) vs. 4.5 cm (4.0–4.9); p=0.048]. Hypopituitarism [partial (n=22, 55%) or complete (n=9, 22.5%)] at diagnosis was present in 77.5% of the patients. Visual field defects were found in 90.9%. The most used surgical technique was endoscopic endonasal transsphenoidal (EET) surgery (n=31, 77.5%). Radiotherapy was used in 11 (27.5%) patients (median dose 50.4 Gy, range 50–54). Thirty-seven patients were followed for 36 months (10–67 months). Although more than half of these patients showed tumor persistence (n=25, 67.6%), tumor size was significantly reduced [0.8 cm (0–2.5); p<0.001]. At last visit, 12 patients (32.4%) showed absence of tumor on MRI. Hypopituitarism rate was similar (75.0%), although with significant changes (p<0.001) in the distribution of the type of hypopituitarism. The absence of tumor at the last visit was positively associated with positive immunohistochemical staining for FSH (p=0.01) and LH (p=0.006) and negatively with female sex (p=0.011), cavernous sinus invasion (p=0.005) and the presence of Knosp grade 4 (p=0.013).

Conclusion gNFPAs are more frequent in men but tumors are larger in women. Surgical treatment is followed by a complete tumor resection rate of approximately 30%. Positive immunostaining for gonadotropins is associated with tumor absence at last revision, while female sex and invasion of the cavernous sinuses with tumor persistence.

Key-words

giant non-functioning pituitary adenoma - hypopituitarism - visual field defects - neurosurgery - and therapeutic outcome

Publikationsverlauf

Eingereicht: 09. Juli 2019
Eingereicht: 09. August 2019

Angenommen: 23. September 2019

Artikel online veröffentlicht:
02. Januar 2020

• References

• 1 Ezzat S, Asa SL, Couldwell WT. et al. The prevalence of pituitary adenomas: A systematic review. Cancer 2004; 101: 613-619
• 2 Dolecek TA, Propp JM, Stroup NE. et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the united states in 2005-2009. Neuro Oncol 2012; 14 Suppl 5 1-49
• 3 Shibui S. The present status and trend of brain tumors based on the data of the brain tumor registry of Japan. Brain Nerve 2012; 64: 286-290
• 4 Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014; 117: 379-394
• 5 Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41: 359-364
• 6 Iglesias P, Arcano K, Triviño V. et al. Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015). Eur J Intern Med 2017; 41: 62-67
• 7 Mohr G, Hardy J, Comtois R. et al. Surgical management of giant pituitary adenomas. Can J Neurol Sci 1990; 17: 62-66
• 8 Trouillas J, Roy P, Sturm N. et al. A new prognostic clinicopathological classification of pituitary adenomas: A multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126: 123-135
• 9 Ceylan S, Anik I, Cabuk B. et al. Extension pathways of pituitary adenomas with cavernous sinus involvement and its surgical approaches. World Neurosurg 2019; 127: e986-e995
• 10 Iglesias P, Rodriguez Berrocal V, Diez JJ. Giant pituitary adenoma: Histological types, clinical features and therapeutic approaches. Endocrine 2018; 61: 407-421
• 11 Goel A, Nadkarni T, Muzumdar D. et al. Giant pituitary tumors: A study based on surgical treatment of 118 cases. Surg Neurol 2004; 61: 436-445
• 12 Maiter D, Delgrange E. Therapy of endocrine disease: The challenges in managing giant prolactinomas. Eur J Endocrinol 2014; 170: R213-R227
• 13 Schaller B. Gender-related differences in non-functioning pituitary adenomas. Neuro Endocrinol Lett 2003; 24: 425-430
• 14 Trott G, Ongaratti BR, de Oliveira Silva CB. et al. PTTG overexpression in non-functioning pituitary adenomas: Correlation with invasiveness, female gender and younger age. Annals of Diagnostic Pathology 2019; 41: 83-89
• 15 Delgrange E, Raverot G, Bex M. et al. Giant prolactinomas in women. Eur J Endocrinol 2013; 170: 31-38
• 16 Shimon I, Sosa E, Mendoza V. et al. Giant prolactinomas larger than 60 mm in size: A cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 2016; 19: 429-436
• 17 Delgrange E, Trouillas J, Maiter D. et al. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82: 2102-2107
• 18 Zhang R, Wang Z, Gao L. et al. Clinical characteristics and postoperative recovery of hypopituitarism in patients with nonfunctional pituitary adenoma. World Neurosurg 2019; Mar 14 pii: S1878-8750(19)30710-7.
• 19 Ogra S, Nichols AD, Stylli S. et al. Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. J Clin Neurosci 2014; 21: 735-740
• 20 Kim TG, Jin KH, Kang J. Clinical characteristics and ophthalmologic findings of pituitary adenoma in korean patients. Int Ophthalmol 2019; 39: 21-31
• 21 Matsuyama J, Kawase T, Yoshida K. et al. Management of large and giant pituitary adenomas with suprasellar extensions. Asian J Neurosurg 2010; 5: 48-53
• 22 Juraschka K, Khan OH, Godoy BL. et al. Endoscopic endonasal transsphenoidal approach to large and giant pituitary adenomas: Institutional experience and predictors of extent of resection. J Neurosurg 2014; 121: 75-83
• 23 Komotar RJ, Starke RM, Raper DM. et al. Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas. Pituitary 2012; 15: 150-159
• 24 Zhao K, Liu X, Liu D. et al. Fractionated gamma knife surgery for giant pituitary adenomas. Clin Neurol Neurosurg 2016; 150: 139-142
• 25 Koutourousiou M, Gardner PA, Fernandez-Miranda JC. et al. Endoscopic endonasal surgery for giant pituitary adenomas: Advantages and limitations. J Neurosurg 2013; 118: 621-631
• 26 Mortini P, Barzaghi R, Losa M. et al. Surgical treatment of giant pituitary adenomas: Strategies and results in a series of 95 consecutive patients. Neurosurgery 2007; 60: 993-1002
• 27 Landeiro JA, Fonseca EO, Monnerat AL. et al. Nonfunctioning giant pituitary adenomas: Invasiveness and recurrence. Surg Neurol Int 2015; 6: 179